Profile data is unavailable for this security.
About the company
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
- Revenue in CAD (TTM)111.95m
- Net income in CAD-9.48m
- Incorporated1995
- Employees103.00
- LocationTheratechnologies Inc2015 Peel Street, 11th FloorMONTREAL H3A 1T8CanadaCAN
- Phone+1 (514) 336-7800
- Fax+1 (514) 331-9691
- Websitehttps://www.theratech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medicus Pharma Ltd | 0.00 | -15.91m | 49.51m | -- | -- | 5.66 | -- | -- | -1.73 | -1.73 | 0.00 | 0.4032 | 0.00 | -- | -- | -- | -267.24 | -652.37 | -371.17 | -- | -- | -- | -- | -- | -- | -20.26 | 0.0549 | -- | -- | -- | -300.86 | -- | -- | -- |
Auxly Cannabis Group Inc | 109.54m | -45.41m | 50.13m | 369.00 | -- | 0.4715 | -- | 0.4576 | -0.0452 | -0.0452 | 0.1012 | 0.0848 | 0.3794 | 2.26 | 6.32 | 296,853.70 | -15.73 | -21.47 | -22.88 | -24.99 | 12.67 | 5.08 | -41.45 | -124.15 | 0.4187 | -1.41 | 0.4279 | -- | 6.99 | 166.85 | 65.84 | -- | -40.92 | -- |
LSL Pharma Group Inc | 14.32m | -2.03m | 54.30m | -- | -- | 2.70 | -- | 3.79 | -0.0232 | -0.0232 | 0.1612 | 0.1743 | 0.4307 | 2.28 | 6.06 | -- | -6.12 | -- | -8.70 | -- | 22.68 | -- | -14.20 | -- | 0.4909 | -0.3722 | 0.4126 | -- | -- | -- | -- | -- | -- | -- |
Medexus Pharmaceuticals Inc | 147.49m | 1.48m | 60.94m | 98.00 | 51.61 | 1.38 | 6.55 | 0.4132 | 0.0483 | 0.0483 | 6.31 | 1.81 | 0.6926 | 1.69 | 5.55 | -- | 0.6952 | -5.03 | 1.33 | -7.77 | 52.50 | 53.26 | 1.00 | -8.05 | 0.4928 | 1.39 | 0.5897 | -- | 4.59 | 34.37 | -117.53 | -- | -9.45 | -- |
Theratechnologies Inc | 111.95m | -9.48m | 75.61m | 103.00 | -- | -- | -- | 0.6754 | -0.2519 | -0.2519 | 2.88 | -0.6843 | 1.19 | 2.70 | 6.36 | 1,086,891.00 | -10.07 | -26.32 | -89.40 | -55.43 | 75.94 | 65.90 | -8.47 | -38.26 | 0.9963 | 0.4497 | 1.64 | -- | 2.13 | 12.58 | 49.28 | -- | -37.83 | -- |
Arch Biopartners Inc | 1.38m | -2.57m | 107.32m | -- | -- | -- | -- | 77.56 | -0.0409 | -0.0409 | 0.0221 | -0.1021 | 0.9363 | -- | 1.88 | -- | -174.05 | -214.82 | -- | -- | -- | -- | -185.89 | -180.45 | -- | -3.57 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Soleus Capital Management LP (Investment Management)as of 04 Apr 2024 | 4.80m | 10.44% |
AIGH Capital Management LLCas of 15 Feb 2024 | 3.72m | 8.09% |
Nantahala Capital Management LLCas of 15 Feb 2024 | 2.68m | 5.83% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.21m | 4.80% |
Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 144.88k | 0.32% |
National Bank Financial, Inc.as of 30 Jun 2024 | 144.38k | 0.31% |
Cyndeo Wealth Partners LLCas of 30 Jun 2024 | 104.12k | 0.23% |
Desjardins Securities, Inc.as of 30 Jun 2024 | 93.01k | 0.20% |
Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Jun 2024 | 80.85k | 0.18% |
Wealthspire Advisors LLCas of 30 Jun 2024 | 51.25k | 0.11% |